삼진제약 005500

http://comp.fnguide.com/SVO2/asp/SVD_Main.asp?pGB=1&gicode=A005500&cID=&MenuYn=Y&ReportGB=&NewMenuID=101&stkGb=701 

삼진제약(A005500) | Snapshot | 기업정보 | Company Guide

- 50년 이상의 업력을 가진 완제 의약품 제조 기업 현재가(원) 19,800 -
  한국기술신용평가㈜ - 2024.05.03 1714691357639.pdf (pstatic.net)
- 전문 합성의약품과 일반의약품 제조 및 판매 - 이베스트증권 - 2023.01.31
  analysis.downpdf (hankyung.com)
- 혈액암 치료제 Apta-16(SJP1604), 美 FDA 희귀의약품 지정 소식에 강세 
  25,200(+3.70%) - 2021.04.01
  ▷압타바이오는 언론을 통해 삼진제약과 공동연구 중인 혈액암 치료제 'Apta-16(SJP1604)'가 
  미국 식품의약국(FDA)의 희귀의약품(Orphan Drug Designation)으로 지정됐다고 밝힘.
  이번 희귀의약품 지정으로 신속 심사, 심사 비용 면제, 임상보조금 지원, 세제 혜택,
  그리고 7년 간 시장독점권 및 임상2상 이후 조건부 판매 허가 등의 혜택을 받을 수 있게 됐음.
  ▷이와 관련 압타바이오 관계자는 "동물실험 결과 해당 약물 투여 결과 생존 기간이 두 배 
  연장되는 효과를 나타냈다"며, "애브비(Abbvie) 의 FDA 승인 약물 베네토클락스(venetoclax)와 
  병용 투여할 경우 약효가 약 20배 증가된 것을 확인했다"고 밝힘.
  이어 "혈액암은 다른 암종과 달리 혈액테스트 결과와 실제 임상 결과가 약 95%가 일치하기 
  때문에 연내 글로벌 빅파마로 기술 수출 계약 가능성이 높다"고 언급했음. 
  [종목] : 삼진제약, 압타바이오
- 퍼스트제네릭 통해 견조한 실적 유지 매수(유지) Target Price 55,000원 
  현재주가(12/14) 40,850원 - 한양증권 - 2018.12.17
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=506021
- 실적은 안정적이나 부담스러운 Multiple MARKETPERFORM TP 62,000원 주가 (9/18)56,100원
  상승여력 10.5% - 현대차투자 - 2018.09.19
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=493969
- 꾸준한 수익성 제고 전망 Buy (maintain) TP 56,000 원 주가 46,650 원 - 
  이베스트증권 - 2018.07.18
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=485555
- 1Q18 Review: 모범적인 제약사 BUY / TP 54,000 원 주가 (4/25) 여력 46,050원 17.3% -
  현대차투자 - 2018.04.26
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=474270
- 수익성 개선세 유효, 저평가 중견제약사 Rating 매수(유지) Target Price 53,000원 
  현재주가(04/20) 45,700원 -  한양증권 - 2018.04.23
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=473524
- Aging에 투자하는 방법 목표주가 44,000원 (4%) 현재주가 42,300원 - 삼성증권 - 2018.02.26 
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=466434
- 수익성 컨센서스 부합 Buy (maintain) TP 50,000 원 주가 40,150 원 - 
  이베스트증권 - 2018.02.02 
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=463194
- 4Q17 Review: 외형보다 이익 BUY / TP 48,000원 현재주가 (1/31) 상승여력 40,150원 19.6% -
  현대차투자 - 2018.02.01
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=462901
- 탄탄한 수익성이 뒷받침 중 매수 (유지) 주가 (1 월 31 일) 40,150 원 TP 45,000 원 (상향) 
  상승여력 12.1% - 신한투자 - 2018.02.01
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=462994
- 만성질환과 고령화 시대의 Winner TP 44,000원 (16.2%) 주가 37,850원 - 삼성증권 - 2018.01.24 
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=461519
- 만성질환 품목 강세 유효 Rating 매수(유지) Target Price 43,000원 Previous 42,000원 -
  한양증권 - 2017.12.11
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=456137

- 3Q17 Review: 높은 이익률 달성 BUY / TP 41,000원 - 현대차투자증권 - 2017.10.26 
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=448242
- 2Q17 Preview: 무난한 성장 BUY / TP 39,000원 - HMC투자 - 2017.07.11-
   http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=434336 
- 1분기 영업이익 112억원(+4.8%, YoY)으로 컨센서스 부합  
-  올해 영업이익 455억원(+8.1%) 전망 
  목표주가 40,000원, 투자의견 ‘매수’ 유지"  - 
  신한투자 -2017.04.27 - 신한20170427삼진제약.pdf